Gland Pharma Limited

rs 25

hip Department Corporate Relationship Department Phiroze Jeejeebhoy Towers Phiroze Jeejeebhoy Towers 25th floor, Dalal Street 25th floor, Dalal Street Mumbai - 400 001 Mumbai - 400 001 Scrip Code: 5432

66%

n PAT PAT % margin(4) % margin(4) 440 440 421 421 14,689 14,689 15,796 15,796 9,370 9,370 66% 66% 3,475 3,475 24% 24% 2,883 2,883 20% 20°/o 1,865 1,865 13% 13% 9,381 9,381 61% 61% 3,58

24%

4) % margin(4) 440 440 421 421 14,689 14,689 15,796 15,796 9,370 9,370 66% 66% 3,475 3,475 24% 24% 2,883 2,883 20% 20°/o 1,865 1,865 13% 13% 9,381 9,381 61% 61% 3,587 3,587 23% 23°/o 2,

20%

0 421 421 14,689 14,689 15,796 15,796 9,370 9,370 66% 66% 3,475 3,475 24% 24% 2,883 2,883 20% 20°/o 1,865 1,865 13% 13% 9,381 9,381 61% 61% 3,587 3,587 23% 23°/o 2,982 2,982 19% 19% 1,

13%

89 15,796 15,796 9,370 9,370 66% 66% 3,475 3,475 24% 24% 2,883 2,883 20% 20°/o 1,865 1,865 13% 13% 9,381 9,381 61% 61% 3,587 3,587 23% 23°/o 2,982 2,982 19% 19% 1,924 1,924 13% 13% -7%

61%

70 9,370 66% 66% 3,475 3,475 24% 24% 2,883 2,883 20% 20°/o 1,865 1,865 13% 13% 9,381 9,381 61% 61% 3,587 3,587 23% 23°/o 2,982 2,982 19% 19% 1,924 1,924 13% 13% -7% -7% 4% 4% -7% -7% 0

23%

75 3,475 24% 24% 2,883 2,883 20% 20°/o 1,865 1,865 13% 13% 9,381 9,381 61% 61% 3,587 3,587 23% 23°/o 2,982 2,982 19% 19% 1,924 1,924 13% 13% -7% -7% 4% 4% -7% -7% 0% 0% 13,841 13,841 5

19%

2,883 20% 20°/o 1,865 1,865 13% 13% 9,381 9,381 61% 61% 3,587 3,587 23% 23°/o 2,982 2,982 19% 19% 1,924 1,924 13% 13% -7% -7% 4% 4% -7% -7% 0% 0% 13,841 13,841 585 585 14,426 14,426

7%

13% 13% 9,381 9,381 61% 61% 3,587 3,587 23% 23°/o 2,982 2,982 19% 19% 1,924 1,924 13% 13% -7% -7% 4% 4% -7% -7% 0% 0% 13,841 13,841 585 585 14,426 14,426 9,213 9,213 67% 67°/o QoQ QoQ

4%

9,381 9,381 61% 61% 3,587 3,587 23% 23°/o 2,982 2,982 19% 19% 1,924 1,924 13% 13% -7% -7% 4% 4% -7% -7% 0% 0% 13,841 13,841 585 585 14,426 14,426 9,213 9,213 67% 67°/o QoQ QoQ 3% 3%

0%

% 61% 3,587 3,587 23% 23°/o 2,982 2,982 19% 19% 1,924 1,924 13% 13% -7% -7% 4% 4% -7% -7% 0% 0% 13,841 13,841 585 585 14,426 14,426 9,213 9,213 67% 67°/o QoQ QoQ 3% 3% -25% -25% 2% 2

67%

,924 13% 13% -7% -7% 4% 4% -7% -7% 0% 0% 13,841 13,841 585 585 14,426 14,426 9,213 9,213 67% 67°/o QoQ QoQ 3% 3% -25% -25% 2% 2% 2% 2% FY25 FY25 FY24 FY24 56,165 56,165 56,647 56,647

“Mn) 79,587 79,587 87,238 87,238 91,507 91,507 ROCE (2) / RONW (3) ROCE (2) / RONW (3> (%) (%) - A - RoCE RoCE RoNW RoNW 11% 11% 11% 11% 11% 11% 9% 9% 9% 8% 8% FY23 FY23 FY24 FY24 FY25 FY25 FY23 FY23 FY24 FY24 FY25 FY25 Capital Expenditure Capital Expenditure (₹ Mn) (?”

“Mn) (₹ Mn) 9,968 9,968 9,147 24,953 24,953 21,756 21,756 25,562 25,562 22,870 22,870 3,640 3,640 FY23 FY23 FY24 FY24 FY25 FY25 FY23 FY23 FY24 FY24 FY25 FY25 Net Working Capital (2) Net Working Capital (2) (?”

“Mn) (₹ Mn) 23,355 21,554 21,554 21,683 21,683 Cash Conversion Cycle (CCC) (3)(4) Cash Conversion Cycle (CCC) (3)(4) (# of Days) (# of Days) 256 256 238 238 98 -80 -80 FY23 FY23 173 152 152 78 -57 FY24 FY24 172 138 138 100 100 -66 FY25 FY25 FY23 FY23 FY24 FY24 FY25 FY25 Receivable days Receivable days Inventory days Inventory days Payable days Payable days Cash conversion cycle Cash conversion cycle 9 1.”

“GLAND Business Update Business Update Base Business (Gland) Updates Base Business (Gland) Updates (cid:127) * (cid:127) (cid:127) (cid:127) (cid:127) (cid:127) (cid:127) ,922 million (4.7% of (cid:127) R&D expenses: R&D expenses were 503 million in Q4 FY25, representing 4.9% of revenue, while for FY25 were • R&D expenses: R&D expenses were ₹503 million in Q4 FY25, representing 4.9% of revenue, while for FY25 were ₹1,922 million (4.7% of revenue).”

“(cid:127) New Launches: Four new molecules, including Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), were • New Launches: Four new molecules, including Latanoprost, Midazolam Bags RTU, Dexamethasone, and Vancomycin (New Strengths), were (cid:127) • (cid:127) • launched in Q4 FY25, contributing to 31 cumulative launches in FY25.”

“launched in Q4 FY25, contributing to 31 cumulative launches in FY25.”

“Filings and approvals: In Q4 FY25, five ANDAs were filed and seven were approved, with a total of 24 ANDAs filed and 32 ANDAs approved in Filings and approvals: In Q4 FY25, five ANDAs were filed and seven were approved, with a total of 24 ANDAs filed and 32 ANDAs approved in FY25, contributing to a cumulative total of 371 ANDA filings in the U.S.”

“FY25, contributing to a cumulative total of 371 ANDA filings in the U.S.”

“(cid:127) Co-development partnership: Fifteen products are under co-development, including six 505(b)(2) and nine ANDAs at various developmental • Co-development partnership: Fifteen products are under co-development, including six 505(b)(2) and nine ANDAs at various developmental stages, are showing promising progress with anticipated commercialization starting from FY27.”

“stages, are showing promising progress with anticipated commercialization starting from FY27.”

Regd. Office

1

Corporate Office

1

Delivery Systems

1

Therapeutic Areas

1

Present in

1

Portfolio evolution on market formation date

1

Co-development Pipeline

1

Focused Outcomes

1

Investor Relations

1

Regd. Office

Survey No. 143-148, 150 & 151, Near Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043,Telangana, India Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office

Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com GLANDI GLAND PHARMA GLAND PHARMA Investor Investor Presentation Presentation Q4 & FY25 Q4 & FY25 20 May 2025 20 May 2025 Safe Harbour Statement Safe Harbour Statement The Presentation is to provide the general background information about the The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor estimates and should not be considered as a recommendation that a

Delivery Systems

• Liquid vials • Lyophilized vials • Pre-filled syringes • Bags • Drops Drops • Pens Pens • Ampoules Ampoules • Cartridges (cid:127) Cartridges

Therapeutic Areas

• Anti-diabetic Anti-diabetic • Anti-infectives Anti-infectives • Anti-malarial Anti-malarial • Anti-neoplastic (Oncology) • Blood-related Blood-related • Cardiac Cardiac • Gastro-intestinal Gastro-intestinal • Hormones Hormones • Neurological and Central Neurological and Central Nervous System Nervous System • Ophthalmics and Otologicals Ophthalmics and Otologicals • Pain, neuro-muscular Pain, neuro-muscular blocking agents & analgesics blocking agents & analgesics • Respiratory Respiratory • Vitamins, minerals & Vitamins, minerals & nutrients nutrients ▪ Dedicated R&D facility at Hyderabad, with on-site support at ■ Dedicated R&D facility at Hyderabad, with on-site support at each manufacturing location, boasts a team of over ~257 each manufacturing location, boasts a team of over -257 professionals, including PhDs, pharmacy post-graduates, and professionals, including PhDs, pharmacy post-graduates, and chemists. chemists. ▪ Scale of expertise enables rapid and efficient development

Present in

▪ Oncology ■ Oncology ▪ Ophthalmics and ■ Ophthalmics and Otologicals Otologicals ■ Blood-related ▪ Blood-related ■ Neurological and ▪ Neurological and Central Nervous Central Nervous System System ■ Pain, neuro-muscular ▪ Pain, neuro-muscular agents and agents and analgesics analgesics Expanding Expanding capabilities in: capabilities in: Expanding in new Expanding in new delivery systems: delivery systems: Key products Key products include: include: ■ Peptides ▪ Peptides ■ Pens ▪ Pens ▪ Cartridges ■ Cartridges ▪ Long-acting ■ Long-acting injectables injectables ▪ Suspensions ■ Suspensions ■ Hormonal products ▪ Hormonal products ▪ Cis-Atracurium ■ Cis-Atracurium Besylate Besylate ▪ Enoxaparin Sodium ■ Enoxaparin Sodium ▪ Heparin Sodium ■ Heparin Sodium ▪ Rocuronium ■ Rocuronium Bromide Bromide Collaborate on co- Collaborate on co- development of development of targeted complex targeted complex injectables with injectables with specialty pharma specialty pharma companies- companies- (c

Portfolio evolution on market formation date

(cid:127) • (cid:127) • (cid:127) • (cid:127) • Genericized portfolio covers a $1.24 billion market with 40 Genericized portfolio covers a $1.24 billion market with 40 ANDAs. ANDAs. Next 1-3 years Market formation: Pipeline to capture a $2.12 Next 1-3 years Market formation: Pipeline to capture a $2.12 billion market with 5 ANDAs. billion market with 5 ANDAs. Beyond 3 years market formation: Strategic investment in Beyond 3 years market formation: Strategic investment in high-growth areas, targeting a $2.34 billion market. high-growth areas, targeting a $2.34 billion market. Total ANDAs in pipeline: 71, with a TAM of $5.71 billion Total ANDAs in pipeline: 71, with a TAM of $5.71 billion 26 26 Complex injectable & co-development pipeline Complex injectable & co-development pipeline Complex R&D pipeline Complex R&D pipeline Co-development Model Co-development Model • • • Developing complex injectables, enhancing formulations, novel drug delivery Developing complex injectables, enhancing